|
Market Closed -
Nasdaq Stockholm
17:00:00 15/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 18.30 SEK | -1.72% |
|
-6.92% | -19.03% |
| 09-07 | Synact surged in Stockholm, the OMXS30 index rose 0.2 percent | FW |
| 09-07 | Rejlers slides on merger plans, OMXS30 index up 0.3 percent | FW |
Company Valuation: SynAct Pharma AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,703 | 2,416 | 314.1 | 416.8 | 1,205 | 1,025 | - | - |
| Change | - | -34.75% | -87% | 32.69% | 189.2% | -14.98% | - | - |
| Enterprise Value (EV) 1 | 3,703 | 2,416 | 314.1 | 370 | 1,152 | 1,050 | 1,099 | 1,025 |
| Change | - | -34.75% | -87% | 17.8% | 211.31% | -8.88% | 4.71% | -6.75% |
| P/E | -53.1x | -22.6x | -1.33x | -4.31x | -10.4x | -10.9x | -18.7x | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.7x | -0x | 0.1x | -2.4x | 0.5x | 0.4x | - |
| Capitalization / Revenue | - | - | - | - | - | 23.2x | 47.4x | 13.2x |
| EV / Revenue | - | - | - | - | - | 23.7x | 50.9x | 13.2x |
| EV / EBITDA | - | - | -1.4x | -4.11x | -9.88x | -22.1x | -33.1x | 36x |
| EV / EBIT | - | - | -1.4x | -4.11x | -9.88x | -22x | -33x | 36x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.68 | -3.6 | -6.64 | -2.08 | -2.17 | -1.68 | -0.98 | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 44.25 | 21.6 | 77.9 |
| EBITDA 1 | - | - | -224.5 | -89.98 | -116.5 | -47.49 | -33.16 | 28.5 |
| EBIT 1 | - | - | -224.5 | -89.98 | -116.5 | -47.75 | -33.29 | 28.5 |
| Net income 1 | -69.3 | -99.2 | -215.8 | -82.4 | -110.8 | -47.08 | -31.92 | 28.5 |
| Net Debt 1 | - | - | - | -46.75 | -53.41 | 24.81 | 74.22 | - |
| Reference price 2 | 142.40 | 81.50 | 8.83 | 8.96 | 22.60 | 18.30 | 18.30 | 18.30 |
| Nbr of stocks (in thousands) | 26,006 | 29,648 | 35,571 | 46,487 | 53,330 | 55,998 | - | - |
| Announcement Date | 11/02/22 | 17/02/23 | 23/02/24 | 18/02/25 | 18/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.89x | 23.72x | -22.1x | - | 105M | |
| 32.3x | 11.75x | 23.82x | 0.61% | 1,013B | |
| 29.72x | 6.61x | 18.51x | 2.01% | 644B | |
| 33.26x | 7.79x | 16.1x | 2.61% | 465B | |
| 19.53x | 4.77x | 11.83x | 2.78% | 352B | |
| 19.64x | 5.13x | 12.73x | 3.13% | 264B | |
| 20.94x | 4.32x | 12.33x | 2.04% | 253B | |
| 23.76x | 6.28x | 11.19x | 2.69% | 203B | |
| 12.28x | 4.47x | 9.35x | 4.09% | 188B | |
| -44.25x | 6.45x | 25.21x | 2.25% | 181B | |
| Average | 13.63x | 8.13x | 11.90x | 2.47% | 356.38B | |
| Weighted average by Cap. | 23.51x | 7.63x | 17.61x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SYNACT Stock
- Valuation SynAct Pharma AB
Select your edition
All financial news and data tailored to specific country editions
